Executive Change · Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of earliest event reported): June 13, 2022   VolitionRx Limited (Exact name of registrant as specified in its charter)   Delaware   001-36833   91-1949078 (State or other jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification Number)     13215 Bee Cave Parkway Suite 125 , Galleria Oaks B Austin , Texas 78738    (Address of principal executive offices and Zip Code)   +1 ( 646 ) 650-1351 (Registrant’s telephone number, including area code )   Not applicable (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Trading Symbol(s)   Name of Each Exchange on which Registered Common Stock   VNRX   NYSE American, LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).    Emerging growth company   ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐         VOLITIONRX LIMITED Form 8-K Current Report   Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.    On June 13, 2022, VolitionRx Limited (the “Company” held its annual meeting of stockholders (the “Annual Meeting”).  At the Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s 2015 Stock Incentive Plan (the “Plan”) to increase the number of shares available for issuance under the Plan by 1,750,000 shares from an aggregate of 6,000,000 shares to 7,750,000 shares.  The Amendment had previously been approved by the Board of Directors of the Company on April 4, 2022, subject to the approval of the Company’s stockholders.  The Plan, as amended by the Amendment, is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.   The foregoing description of the Amendment of the Plan does not purport to be complete and is qualified in its entirety by reference to such Exhibit 10.1.    Item 5.07 Submission of Matters to a Vote of Security Holders.   At the Annual Meeting held at 11:00 a.m. local time on June 13, 2022 at 93-95 Gloucester Place, London, W1U 6JQ, United Kingdom, the Company’s stockholders voted on four proposals. The Company had 53,790,261 shares of common stock outstanding on April 18, 2022, the record date for the Annual Meeting, of which 36,424,257 shares of common stock were present in person or represented by proxy at the Annual Meeting. The matters voted on at the Annual Meeting are described in more detail in the Company’s definitive proxy statement on Schedule 14A, which the Company filed with the Securities and Exchange Commission on April 28, 2022 (the “ Proxy Statement ”).   The following proposals were voted upon at the Annual Meeting and the final voting results with respect to each proposal are set forth below:   Proposal 1 : The Company’s stockholders elected eight members to the Board of Directors to hold office until the 2023 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier resignation or removal. The voting results were as follows:   Nominee   Votes For     Votes Withheld     Broker Non-Votes   Cameron Reynolds     14,564,225       12,094,546       9,765,486   Dr. Martin Faulkes     14,593,614       12,065,157       9,765,486   Guy Innes     14,084,291       12,574,480       9,765,486   Dr. Alan Colman     26,570,337       88,434       9,765,486   Dr. Phillip Barnes     26,576,440       82,331       9,765,486   Dr. Edward Futcher     26,022,538       636,233       9,765,486   Kim Nguyen     26,352,676       306,095       9,765,486   Richard Brudnick     26,573,862       84,909       9,765,486     Proposal 2 : The Company’s stockholders ratified the selection of Sadler, Gibb & Associates, LLC as the Company’s independent registered public accounting firm for the year ending December 31, 2022. The voting results were as follows:   Votes For   Votes Against   Votes Abstained   36,233,844   169,853   20,560     Proposal 3 : The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as described in the Proxy Statement. The voting results were as follows:   Votes For   Votes Against   Votes Abstained   Broker Non-Votes 14,167,283   12,227,418   264,070   9,765,486       2     Proposal 4 : The Company’s stockholders approved an amendment to the Company’s 2015 Stock Incentive Plan. The voting results were as follows:   Votes For   Votes Against   Votes Abstained   Broker Non-Votes 14,107,753   12,366,590   184,428   9,765,486     No other matters were presented for consideration or stockholder action at the Annual Meeting.   Item 9.01 Financial Statements and Exhibits.   (d) Exhibits   Exhibit Number   Description     10.1   2015 Stock Incentive Plan, as amended       104   Cover Page Interactive Data File (embedded within the inline XRBL document).     3     SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     VOLITIONRX LIMITED     Date: June 14, 2022 By: /s/ Cameron Reynolds     Cameron Reynolds       Chief Executive Officer & President       4      EXHIBIT INDEX   Exhibit Number   Description     10.1   2015 Stock Incentive Plan, as amended       104   Cover Page Interactive Data File (embedded within the inline XRBL document).     5